Survodutide has a novel mechanism of action (agonism of the dual GCG/GLP-1 receptors) that may have direct effects on energy expenditure in the liver in addition to decreasing appetite
Nous-209 has been developed using the Nouscom's viral vector platform
Study efficacy measures will include the expression of dystrophin protein and motor function.
AUR101, with a good ADME/PK profile and high bioavailability, has demonstrated inhibition of IL-17A in whole blood from psoriasis patients
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
Results reinforce commitment to next-generation oral SERD development programme
High-level results from the MESSINA Phase III trial showed that AstraZeneca's Fasenra (benralizumab) did not meet one of the two dual-primary endpoints.
New data from Boehringer Ingelheim support the potential use of nintedanib in children and adolescents with fibrosing interstitial lung disease
The OCEANIC program will start with two Phase III studies investigating the efficacy and safety of asundexian in prevention of stroke
Amarex Clinical Research guides its client to phase II of FDA trials
Subscribe To Our Newsletter & Stay Updated
